Improving cancer outcomes with Radioligand Therapies
Founded in late 2019, POINT Biopharma is a clinical-stage global pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Radioligands offer improved efficacy and superior safety profiles versus platform chemotherapy agents and can provide patients and their families the very best possible outcomes.
We are dedicated to expanding access to radioligand therapies, making them applicable to more cancers, accessible to more people, and improving the lives of patients and their families. Here are the compounds we are currently developing:
PNT2001
Currently at the pre-clinical stage, PNT2001 is a radioligand based therapy for treating prostate cancer.
Learn more about our Prostate Cancer Treatment >
PNT2001
Currently at the pre-clinical stage, PNT2001 is a radioligand based therapy for treating prostate cancer.
Learn more about our Prostate Cancer Treatment >
PNT2001
Currently at the pre-clinical stage, PNT2001 is a radioligand based therapy for treating prostate cancer.
Learn more about our Prostate Cancer Treatment >
PNT2001
Currently at the pre-clinical stage, PNT2001 is a radioligand based therapy for treating prostate cancer.
Learn more about our Prostate Cancer Treatment >
Help improve the lives of patients and their families
We are hiring for clinical, manufacturing and business roles
